Ameriderm Research announce a new clinical trial is for patients aged 18 to 75 with moderate to severe plaque psoriasis. It involves administering oral medication as a Phase II double-blind, randomized, placebo controlled assessment of safety and efficacy. The trials lasts up to 40 12 weeks of treatment and 1 month follow-up. A long term extension study is available to qualifying patients.
The trial is expected to enroll quickly. To see if you qualify please call (386) 523-0768 today.